<?xml version="1.0" encoding="UTF-8" standalone="yes"?><?xml-stylesheet type="text/xsl" href="/oai-pmh-repository/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2026-10-15T07:25:42Z</responseDate>
    <request verb="GetRecord" identifier="oai:data.mendeley.com/3x3zd3zvhm.2" metadataPrefix="oai_dc">https://data.mendeley.com/oai</request>
    <GetRecord>
        <record>
            <header>
                <identifier>oai:data.mendeley.com/3x3zd3zvhm.2</identifier>
                <datestamp>2020-01-05T12:43:17Z</datestamp>
            </header>
            <metadata><oai_dc:dc xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <dc:creator>Pondorfer, Prisca</dc:creator>
    <dc:title>C-reactive protein in patients with HPVp16-negative oropharyngeal squamous cell carcinoma. A single center retrospective study. </dc:title>
    <dc:publisher>Mendeley Data</dc:publisher>
    <dc:description>Objectives: Elevated C-reactive protein (CRP) is associated with poor prognosis in several solid cancers. Reliable prognostic markers are lacking for papillomavirus (HPVp16)-negative oropharyngeal squamous cell carcinoma (OPSCC). This study was performed to investigate the role of CRP in prognosis of patients with HPVp16- negative oropharyngeal cancer.  

Design: We retrospectively analyzed data of 85 consecutive patients treated for OPSCC of a single center in Austria from 2013-2015. Information of performed examinations prior to treatment, CT and MR imaging, levels of C-reactive protein and fibrinogen, neutrophils and lymphocytes were retrospectively analyzed. Kaplan-Meier and Cox regression models were used to determine overall survival (OS) and recurrence-free survival (RFS) by CRP level in both populations. CRP cut-off Levels were defined by ROC curve at 13,6 mg/L.

Results: Absolute CRP levels between HPVp16-positive and HPVp16-negative patients did not differ significantly. In the overall cohort elevated CRP levels (&gt;13,6 mg/L) were associated with reduced overall survival (P=.01) and recurrence-free survival (P&lt; .001).  Within the HPVp16-negative group OS and RFS were significantly reduced in patients with elevated CRP levels (p&lt;.001 and p&lt;.001, respectively) in univariate and multivariate analysis, whereas no significant differences could be found with the HPVp16-positive group in OS and DFS.

Conclusion: Patients with HPVp16-negative OPSCC and elevated CRP level at 13,6 mg/L prior to therapy showed significantly reduced OS and RFS, whereas among HPVp16-positive patients elevated CRP levels did not show any impact on OS or RFS.
</dc:description>
    <dc:subject>Head and Neck Cancer</dc:subject>
    <dc:type>Dataset</dc:type>
    <dc:identifier>doi:10.17632/3x3zd3zvhm.2</dc:identifier>
    <dc:identifier>oai:data.mendeley.com/3x3zd3zvhm.2</dc:identifier>
    <dc:rights>Creative Commons Attribution 4.0 International</dc:rights>
    <dc:rights>http://creativecommons.org/licenses/by/4.0</dc:rights>
    <dc:relation>https://data.mendeley.com/datasets/3x3zd3zvhm</dc:relation>
    <dc:date>2020-01-05T12:43:17Z</dc:date>
    <dc:date>2021-01-02T00:00:00Z</dc:date>
</oai_dc:dc></metadata>
        </record>
    </GetRecord>
</OAI-PMH>
